Vivos Therapeutics implements 1-for-25 reverse stock split to meet Nasdaq minimum bid price

Vivos Therapeutics, Inc.

Reverse stock split at 1:25 ratio effective October 25, 2023; shares reduced from ~29.9M to ~1.2M.
Common stock began trading on post-split basis on Nasdaq under same ticker VVOS on October 27, 2023.
No fractional shares issued; fractional shares rounded up to nearest whole share.
Split approved by board under stockholder authority granted at 2023 Annual Meeting on September 22, 2023.
Company aims to satisfy $1.00 minimum bid price requirement for continued Nasdaq listing under Rule 5550(a)(2).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Vivos Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-25 reverse stock split (effective 2023-10-25).

Change: charter amendment
Effective: 2023-10-25

Exact text from the filing

On October 25, 2023, Vivos Therapeutics, Inc. (the “ Company ”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation with the Secretary of State of Delaware (the “ Certificate of Amendment ”) to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ”) at a ratio of 1-for-25 (the “ Reverse Stock Split ”).

View on SEC.gov

Browse all governance changes →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-038523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.